Common TitleRESOLVE
Official Title A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)
Purpose / DescriptionThis trial was an open-label, phase 2b trial to evaluate the efficacy of a fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir for 12 weeks in adults with chronic HCV GT 1 infection and a history of virologic rebound following DAA therapy. With an intent-to-treat analysis, the overall SVR12 rate was 91% (70 of 77). Using a per protocol analysis, the SVR12 rate was 99% (70 of 71). Among the study participants with HIV, 82% (14 of 17) achieved an SVR12
Phase Phase IIB
ClinicalTrials.gov NCT02745535
Treatments
Sofosbuvir-Velpatasvir-Voxilaprevir

Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedFunding
IndustryGilead Sciences
Non-IndustryIntramural Research Pro- gram of the NIH, Clinical Center